Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)

This study has been completed.
Sponsor:
Information provided by:
Tottori University Hospital
ClinicalTrials.gov Identifier:
NCT00664222
First received: April 18, 2008
Last updated: April 21, 2008
Last verified: April 2008
  Purpose

The purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.


Condition Intervention Phase
Chronic Stable Heart Failure
Drug: spironolactone + furosemide
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Spironolactone on Insulin Resistance in Patients With Chronic Heart Failure

Resource links provided by NLM:


Further study details as provided by Tottori University Hospital:

Primary Outcome Measures:
  • insulin resistance [ Time Frame: 16 weeks ]

Enrollment: 16
Study Start Date: January 2004
Estimated Study Completion Date: December 2005
Intervention Details:
    Drug: spironolactone + furosemide
    spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
Detailed Description:

Diuretics is useful in CHF patients. On the other hand, they deteriorate glucose metabolism. Therefore, the purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • chronic stable heart failure

Exclusion Criteria:

  • renal dysfunction or under treatment with antidiabetic agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Kazuhide Ogino, MD, Center for Clinical Residency Program, Tottori University Hospital
ClinicalTrials.gov Identifier: NCT00664222     History of Changes
Other Study ID Numbers: #344.1
Study First Received: April 18, 2008
Last Updated: April 21, 2008
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Tottori University Hospital:
heart failure
insulin resistance
inflammatory cytokine
spironolactone
furosemide

Additional relevant MeSH terms:
Heart Failure
Insulin Resistance
Heart Diseases
Cardiovascular Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Insulin
Furosemide
Spironolactone
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Diuretics
Natriuretic Agents
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Therapeutic Uses
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Diuretics, Potassium Sparing

ClinicalTrials.gov processed this record on September 18, 2014